	US 12,133,844 B2
	Methods of treating epithelioid cell tumors
Neil P. Desai, Pacific Palisades, CA (US)
Assigned to Abraxis BioScience, LLC, Summit, NJ (US)
Filed by Abraxis BioScience, LLC, Summit, NJ (US)
Filed on Feb. 2, 2021, as Appl. No. 17/165,652.
Application 17/165,652 is a continuation of application No. 15/737,936, granted, now 10,973,806, previously published as PCT/US2016/040170, filed on Jun. 29, 2016.
Claims priority of provisional application 62/186,252, filed on Jun. 29, 2015.
Prior Publication US 2021/0322391 A1, Oct. 21, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/436 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/10 (2006.01); A61K 9/19 (2006.01); A61K 9/51 (2006.01); A61K 38/38 (2006.01); A61K 47/42 (2017.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01)

CPC A61K 31/436 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 9/10 (2013.01); A61K 9/19 (2013.01); A61K 9/5169 (2013.01); A61K 38/38 (2013.01); A61K 47/42 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01)]

14 Claims

1. A method of treating a malignant perivascular epithelioid tumor (PEComa) in an individual, comprising intravenously administering to the individual an effective amount of a composition comprising nanoparticles comprising sirolimus and an albumin, wherein the effective amount of sirolimus in the nanoparticle composition is about 10 mg/m²to about 100 mg/m², and wherein the nanoparticle composition is administered on days 1 and 8 of a 21-day cycle.